AUPH logo

AUPH
Aurinia Pharmaceuticals Inc

46,469
Mkt Cap
$1.9B
Volume
498.00
52W High
$16.54
52W Low
$6.83
PE Ratio
6.73
AUPH Fundamentals
Price
$13.98
Prev Close
$14.27
Open
$14.30
50D MA
$14.48
Beta
0.84
Avg. Volume
899,237.89
EPS (Annual)
$2.07
P/B
3.18
Rev/Employee
$2.21M
$1,889.08
Loading...
Loading...
News
all
press releases
Aurinia Pharmaceuticals to Acquire Kezar Life Sciences for $6.955 in Cash per Share Plus a Contingent Value Right
Aurinia Pharmaceuticals Inc. (NASDAQ: AUPH), a biopharmaceutical company focused on delivering therapies to people living with autoimmune diseases with high unmet medical needs, announced today it...
Business Wire·23h ago
News Placeholder
More News
News Placeholder
AUPH Stock Rallies After CEO Shake-Up: Retail Bulls Bet On Turnaround
Aurinia Pharmaceuticals named Kevin Tang as its Chief Executive Officer, replacing Peter Greenleaf.
Stocktwits·8d ago
News Placeholder
Why Aurinia Pharmaceuticals Stock Is Surging Monday Morning
Aurinia Pharmaceuticals shares are trading higher Monday after announcing a leadership transition seen as a sign of continuity and strategy.read more...
Benzinga·8d ago
News Placeholder
Aurinia Announces Management Transition
Aurinia Pharmaceuticals Inc. (NASDAQ: AUPH) announced today that Kevin Tang, Aurinias Chair of the Board, will succeed Peter Greenleaf as Chief Executive Officer. Peter will continue as a consultant...
Business Wire·8d ago
News Placeholder
Aurinia Pharmaceuticals (NASDAQ:AUPH) Stock Passes Below 200-Day Moving Average - Here's What Happened
Aurinia Pharmaceuticals (NASDAQ:AUPH) Stock Crosses Below 200-Day Moving Average - Time to Sell...
MarketBeat·11d ago
News Placeholder
Aurinia Pharmaceuticals Inc (NASDAQ:AUPH) Receives Average Recommendation of "Hold" from Analysts
Shares of Aurinia Pharmaceuticals Inc (NASDAQ:AUPH - Get Free Report) (TSE:AUP) have been assigned a consensus rating of "Hold" from the six analysts that are currently covering the company...
MarketBeat·19d ago
News Placeholder
Aurinia Pharmaceuticals (NASDAQ:AUPH) Stock Passes Below 50-Day Moving Average - Should You Sell?
Aurinia Pharmaceuticals (NASDAQ:AUPH) Stock Crosses Below 50 Day Moving Average - Here's What Happened...
MarketBeat·20d ago
News Placeholder
Aurinia Pharmaceuticals (NASDAQ:AUPH) Director Buys $7,224,981.61 in Stock
Aurinia Pharmaceuticals Inc (NASDAQ:AUPH - Get Free Report) (TSE:AUP) Director Kevin Tang purchased 516,439 shares of Aurinia Pharmaceuticals stock in a transaction dated Friday, February 27th. The...
MarketBeat·27d ago
News Placeholder
GSA Capital Partners LLP Trims Stake in Aurinia Pharmaceuticals Inc $AUPH
GSA Capital Partners LLP trimmed its position in Aurinia Pharmaceuticals Inc (NASDAQ:AUPH - Free Report) (TSE:AUP) by 95.9% in the 3rd quarter, according to its most recent 13F filing with the...
MarketBeat·28d ago
News Placeholder
Aurinia Pharmaceuticals (NASDAQ:AUPH) Posts Earnings Results
Aurinia Pharmaceuticals (NASDAQ:AUPH - Get Free Report) (TSE:AUP) issued its quarterly earnings results on Thursday. The biotechnology company reported $1.53 earnings per share (EPS) for the quarter...
MarketBeat·1mo ago
<
1
2
...
>

Latest AUPH News

View
Top Discussions

Advertisement|Remove ads.

Advertisement|Remove ads.